Management of women with uterine papillary serous cancer: A Society of Gynecologic Oncology (SGO) review

Gynecologic Oncology

Volumn 115, Issue 1, 2009, Pages 142-153

  Boruta II, David M ^a   Gehrig, Paola A ^b   Fader, Amanda Nickles ^c   Olawaiye, Alexander B ^d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapy; Endometrial cancer; Radiotherapy; Staging; Uterine papillary serous carcinoma

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL; TRASTUZUMAB;

ALGORITHM; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER CYTODIAGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CARCINOGENESIS; CLINICAL FEATURE; CYTOREDUCTIVE SURGERY; ENDOMETRIUM CARCINOMA; FOLLOW UP; HUMAN; MEDICAL SOCIETY; MEDLINE; MULTIMODALITY CANCER THERAPY; NEUROTOXICITY; OUTCOME ASSESSMENT; PATIENT MONITORING; PELVIS LYMPHADENECTOMY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADICAL HYSTERECTOMY; RECURRENCE RISK; REVIEW; TREATMENT PLANNING; UTERUS PAPILLARY SEROUS CANCER;

CARCINOMA, PAPILLARY; COMBINED MODALITY THERAPY; CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; UTERINE NEOPLASMS;

EID: 69249217765     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.06.011     Document Type: Review

References (147)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2008. CA Cancer J. Clin. 58 2 (2008 Mar-Apr) 71-96
2. Ueda S.M., Kapp D.S., Cheung M.K., Shin J.Y., Osann K., Husain A., et al. Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. Am. J. Obstet. Gynecol. 198 2 (2008) 218 e1-6
3. Cirisano Jr. F.D., Robboy S.J., Dodge R.K., Bentley R.C., Krigman H.R., Synan I.S., et al. Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma. Gynecol. Oncol. 74 3 (1999) 385-394
4. Hamilton C.A., Cheung M.K., Osann K., Chen L., Teng N.N., Longacre T.A., et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br. J. Cancer 94 5 (2006) 642-646
5. Lauchlan S.C. Tubal (serous) carcinoma of the endometrium. Arch. Pathol. Lab. Med. 105 11 (1981 Nov) 615-618
6. Hendrickson M., Ross J., Eifel P., Martinez A., and Kempson R. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am. J. Surg. Pathol. 6 2 (1982 Mar) 93-108
7. Bokhman J.V. Two pathogenetic types of endometrial carcinoma. Gynecol. Oncol. 15 1 (1983 Feb) 10-17
8. Bjorge T., Engeland A., Tretli S., and Weiderpass E. Body size in relation to cancer of the uterine corpus in 1 million Norwegian women. Int. J. Cancer 120 2 (2007 Jan 15) 378-383
9. McCullough M.L., Patel A.V., Patel R., Rodriguez C., Feigelson H.S., Bandera E.V., et al. Body mass and endometrial cancer risk by hormone replacement therapy and cancer subtype. Cancer Epidemiol., Biomarkers Prev. 17 1 (2008) 73-79
10. Lachance J.A., Everett E.N., Greer B., Mandel L., Swisher E., Tamimi H., et al. The effect of age on clinical/pathologic features, surgical morbidity, and outcome in patients with endometrial cancer. Gynecol. Oncol. 101 3 (2006 Jun) 470-475
11. Matthews R.P., Hutchinson-Colas J., Maiman M., Fruchter R.G., Gates E.J., Gibbon D., et al. Papillary serous and clear cell type lead to poor prognosis of endometrial carcinoma in black women. Gynecol. Oncol. 65 2 (1997 May) 206-212
12. Sherman M.E., and Devesa S.S. Analysis of racial differences in incidence, survival, and mortality for malignant tumors of the uterine corpus. Cancer 98 1 (2003 Jul 1) 176-186
13. Maxwell G.L., Tian C., Risinger J., Brown C.L., Rose G.S., Thigpen J.T., et al. Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma: a Gynecologic Oncology Group study. Cancer 107 9 (2006) 2197-2205
14. Farley J., Risinger J.I., Rose G.S., and Maxwell GL. Racial disparities in blacks with gynecologic cancers. Cancer 110 2 (2007 Jul 15) 234-243
15. Soslow R.A., Bissonnette J.P., Wilton A., Ferguson S.E., Alektiar K.M., Duska L.R., et al. Clinicopathologic analysis of 187 high-grade endometrial carcinomas of different histologic subtypes: similar outcomes belie distinctive biologic differences. Am. J. Surg. Pathol. 31 7 (2007) 979-987
16. Ambros R.A., Sherman M.E., Zahn C.M., Bitterman P., and Kurman R.J. Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. Hum. Pathol. 26 11 (1995 Nov) 1260-1267
17. Sherman M.E., Bitterman P., Rosenshein N.B., Delgado G., and Kurman R.J. Uterine serous carcinoma. A morphologically diverse neoplasm with unifying clinicopathologic features. Am. J. Surg. Pathol. 16 6 (1992 Jun) 600-610
18. Yi X., and Zheng W. Endometrial glandular dysplasia and endometrial intraepithelial neoplasia. Curr. Opin. Obstet. Gynecol. 20 1 (2008) 20-25
19. Zheng W., Liang S.X., Yi X., Ulukus E.C., Davis J.R., and Chambers S.K. Occurrence of endometrial glandular dysplasia precedes uterine papillary serous carcinoma. Int. J. Gynecol. Pathol. 26 1 (2007) 38-52
20. Zheng W., Liang S.X., Yu H., Rutherford T., Chambers S.K., and Schwartz P.E. Endometrial glandular dysplasia: a newly defined precursor lesion of uterine papillary serous carcinoma. Part I: morphologic features. Int J Surg Pathol. 12 3 (2004 Jul) 207-223
21. Hecht J.L., and Mutter G.L. Molecular and pathologic aspects of endometrial carcinogenesis. J. Clin. Oncol. 24 29 (2006) 4783-4791
22. Zheng W., Cao P., Zheng M., Kramer E.E., and Godwin T.A. p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes. Gynecol. Oncol. 61 2 (1996 May) 167-174
23. Santin A.D., Bellone S., Gokden M., Palmieri M., Dunn D., Agha J., et al. Overexpression of HER-2/neu in uterine serous papillary cancer. Clin. Cancer Res. 8 5 (2002) 1271-1279
24. Goshen R., Chu W., Elit L., Pal T., Hakimi J., Ackerman I., et al. Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome?. Gynecol. Oncol. 79 3 (2000 Dec) 477-481
25. Lavie O., Hornreich G., Ben Arie A., Renbaum P., Levy-Lahad E., and Beller U. BRCA1 germline mutations in women with uterine serous papillary carcinoma. Obstet. Gynecol. 96 1 (2000) 28-32
26. Lavie O., Hornreich G., Ben-Arie A., Rennert G., Cohen Y., Keidar R., et al. BRCA germline mutations in Jewish women with uterine serous papillary carcinoma. [see comment]. Gynecol. Oncol. 92 2 (2004) 521-524
27. Levine D.A., Lin O., Barakat R.R., Robson M.E., McDermott D., Cohen L., et al. Risk of endometrial carcinoma associated with BRCA mutation. Gynecol. Oncol. 80 3 (2001 Mar) 395-398
28. Geisler J.P. Patients having prophylactic surgery for family history or known genetic mutations: why save the uterus?. Gynecol. Oncol. 104 3 (2007 Mar) 780-781
29. Barakat R.R., Wong G., Curtin J.P., Vlamis V., and Hoskins W.J. Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features. Gynecol. Oncol. 55 2 (1994 Nov) 164-168
30. Bergman L., Beelen M.L., Gallee M.P., Hollema H., Benraadt J., and van Leeuwen F.E. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of liver and endometrial cancer risk following tamoxifen. Lancet 356 9233 (2000 Sep 9) 881-887
31. Fisher B., Costantino J.P., Wickerham D.L., Cecchini R.S., Cronin W.M., Robidoux A., et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J. Natl. Cancer Inst. 97 22 (2005 Nov 16) 1652-1662
32. Gehrig P.A., Bae-Jump V.L., Boggess J.F., Groben P.A., Fowler Jr. W.C., and Van Le L. Association between uterine serous carcinoma and breast cancer. Gynecol. Oncol. 94 1 (2004) 208-211
33. Magriples U., Naftolin F., Schwartz P.E., and Carcangiu M.L. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J. Clin. Oncol. 11 3 (1993 Mar) 485-490
34. Mignotte H., Lasset C., Bonadona V., Lesur A., Luporsi E., Rodier J.F., et al. Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study. Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC). Int. J. Cancer 76 3 (1998 May 4) 325-330
35. Saadat M., Truong P.T., Kader H.A., Speers C.H., Berthelet E., McMurtrie E., et al. Outcomes in patients with primary breast cancer and a subsequent diagnosis of endometrial cancer: comparison of cohorts treated with and without tamoxifen. Cancer 110 1 (2007) 31-37
36. Silva E.G., Tornos C.S., and Follen-Mitchell M. Malignant neoplasms of the uterine corpus in patients treated for breast carcinoma: the effects of tamoxifen. Int. J. Gynecol. Pathol. 13 3 (1994 Jul) 248-258
37. Chan J.K., Manuel M.R., Cheung M.K., Osann K., Husain A., Teng N.N., et al. Breast cancer followed by corpus cancer: is there a higher risk for aggressive histologic subtypes?. Gynecol. Oncol. 102 3 (2006) 508-512
38. Geisler J.P., Sorosky J.I., Duong H.L., Buekers T.E., Geisler M.J., Sood A.K., et al. Papillary serous carcinoma of the uterus: increased risk of subsequent or concurrent development of breast carcinoma. Gynecol. Oncol. 83 3 (2001) 501-503
39. Dunton C.J., Balsara G., McFarland M., and Hernandez E. Uterine papillary serous carcinoma: a review. Obstet. Gynecol. Surv. 46 2 (1991 Feb) 97-102
40. Creasman W.T., Kohler M.F., Odicino F., Maisonneuve P., and Boyle P. Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium. Gynecol. Oncol. 95 3 (2004) 593-596
41. Slomovitz B.M., Burke T.W., Eifel P.J., Ramondetta L.M., Silva E.G., Jhingran A., et al. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. [see comment]. Gynecol. Oncol. 91 3 (2003) 463-469
42. Alektiar K.M., McKee A., Lin O., Venkatraman E., Zelefsky M.J., McKee B., et al. Is there a difference in outcome between stage I-II endometrial cancer of papillary serous/clear cell and endometrioid FIGO Grade 3 cancer?. Int. J. Radiat. Oncol. Biol. Phys 54 1 (2002 Sep 1) 79-85
43. Boruta II D.M., Gehrig P.A., Groben P.A., Bae-Jump V., Boggess J.F., Fowler Jr. W.C., et al. Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference?. Cancer 101 10 (2004) 2214-2221
44. Halperin R., Zehavi S., Langer R., Hadas E., Bukovsky I., and Schneider D. Uterine papillary serous carcinoma (pure and mixed type) compared with moderately and poorly differentiated endometrioid carcinoma. A clinicopathologic study. Eur. J. Gynaecol. Oncol. 23 4 (2002) 300-304
45. Singh P., Smith C.L., Cheetham G., Dodd T.J., and Davy M.L. Serous carcinoma of the uterus-determination of HER-2/neu status using immunohistochemistry, chromogenic in situ hybridization, and quantitative polymerase chain reaction techniques: its significance and clinical correlation. Int. J. Gynecol. Cancer 18 (6): (2008 Nov-Dec) 1344-1351
46. Slomovitz B.M., Broaddus R.R., Burke T.W., Sneige N., Soliman P.T., Wu W., et al. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J. Clin. Oncol. 22 15 (2004 Aug 1) 3126-3132
47. Villella J.A., Cohen S., Smith D.H., Hibshoosh H., and Hershman D. HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications. Int. J. Gynecol. Cancer 16 5 (2006 Sep-Oct) 1897-1902
48. Santin A.D., Bellone S., Van Stedum S., Bushen W., Palmieri M., Siegel E.R., et al. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma. Cancer 104 7 (2005) 1391-1397
49. Odicino F.E., Bignotti E., Rossi E., Pasinetti B., Tassi R.A., Donzelli C., et al. HER-2/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization. Int. J. Gynecol. Cancer 18 1 (2008) 14-21
50. Risinger J.I., Maxwell G.L., Chandramouli G.V., Jazaeri A., Aprelikova O., Patterson T., et al. Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer. Cancer Res. 63 1 (2003 Jan 1) 6-11
51. Zorn K.K., Bonome T., Gangi L., Chandramouli G.V., Awtrey C.S., Gardner G.J., et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin. Cancer Res. 11 18 (2005) 6422-6430
52. Carcangiu M.L., Tan L.K., and Chambers J.T. Stage IA uterine serous carcinoma: a study of 13 cases. Am. J. Surg. Pathol. 21 12 (1997 Dec) 1507-1514
53. Gehrig P.A., Groben P.A., Fowler Jr. W.C., Walton L.A., and Van Le L. Noninvasive papillary serous carcinoma of the endometrium. Obstet. Gynecol. 97 1 (2001) 153-157
54. Goff B.A., Kato D., Schmidt R.A., Ek M., Ferry J.A., Muntz H.G., et al. Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol. Oncol. 54 3 (1994 Sep) 264-268
55. Silva E.G., and Jenkins R. Serous carcinoma in endometrial polyps. Mod Pathol. Mar 3 2 (1990) 120-128
56. Wheeler D.T., Bell K.A., Kurman R.J., and Sherman M.E. Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation. Am. J. Surg. Pathol. 24 6 (2000 Jun) 797-806
57. Lee K.R., and Belinson J.L. Recurrence in noninvasive endometrial carcinoma. Relationship to uterine papillary serous carcinoma. Am. J. Surg. Pathol. 15 10 (1991 Oct) 965-973
58. Zheng W., and Schwartz P.E. Serous EIC as an early form of uterine papillary serous carcinoma: recent progress in understanding its pathogenesis and current opinions regarding pathologic and clinical management. Gynecol. Oncol. 96 3 (2005) 579-582
59. Huang G.S., Gebb J.S., Einstein M.H., Shahabi S., Novetsky A.P., and Goldberg G.L. Accuracy of preoperative endometrial sampling for the detection of high-grade endometrial tumors. Am. J. Obstet. Gynecol. 196 3 (2007) 243 e1-5
60. Wang J., Wieslander C., Hansen G., Cass I., Vasilev S., and Holschneider C.H. Thin endometrial echo complex on ultrasound does not reliably exclude type 2 endometrial cancers. Gynecol. Oncol. 101 1 (2006) 120-125
61. Grigoriou O., Kalovidouros A., Papadias C., Antoniou G., Antonaki V., and Giannikos L. Transvaginal sonography of the endometrium in women with postmenopausal bleeding. Maturitas 23 1 (1996 Feb) 9-14
62. Despierre E., Moerman P., Vergote I., and Amant F. Is there a role for neoadjuvant chemotherapy in the treatment of stage IV serous endometrial carcinoma?. Int. J. Gynecol. Cancer 16 Suppl 1 (2006) 273-277
63. Le T.D., Yamada S.D., Rutgers J.L., and DiSaia P.J. Complete response of a stage IV uterine papillary serous carcinoma to neoadjuvant chemotherapy with Taxol and carboplatin. Gynecol. Oncol. 73 3 (1999 Jun) 461-463
64. Price F.V., Amin R.M., and Sumkin J. Complete clinical responses to neoadjuvant chemotherapy for uterine serous carcinoma. Gynecol. Oncol. 73 1 (1999 Apr) 140-144
65. Resnik E., and Taxy J.B. Neoadjuvant chemotherapy in uterine papillary serous carcinoma. Gynecol. Oncol. 62 1 (1996 Jul) 123-127
66. Chan J.K., Cheung M.K., Huh W.K., Osann K., Husain A., Teng N.N., et al. Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients. Cancer 107 8 (2006 Oct 15) 1823-1830
67. Kitchener H., Swart A.M., Qian Q., Amos C., and Parmar M.K. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 373 9658 (2009 Jan 10) 125-136
68. Carcangiu M.L., and Chambers J.T. Uterine papillary serous carcinoma: a study on 108 cases with emphasis on the prognostic significance of associated endometrioid carcinoma, absence of invasion, and concomitant ovarian carcinoma. Gynecol. Oncol. 47 3 (1992 Dec) 298-305
69. Hui P., Kelly M., O'Malley D.M., Tavassoli F., and Schwartz P.E. Minimal uterine serous carcinoma: a clinicopathological study of 40 cases. Mod. Path. 18 1 (2005) 75-82
70. Chan J.K., Loizzi V., Youssef M., Osann K., Rutgers J., Vasilev S.A., et al. Significance of comprehensive surgical staging in noninvasive papillary serous carcinoma of the endometrium. Gynecol. Oncol. 90 1 (2003) 181-185
71. Turner B.C., Knisely J.P., Kacinski B.M., Haffty B.G., Gumbs A.A., Roberts K.B., et al. Effective treatment of stage I uterine papillary serous carcinoma with high dose-rate vaginal apex radiation (192Ir) and chemotherapy. Int. J. Radiat. Oncol. Biol. Phys. 40 1 (1998 Jan 1) 77-84
72. Fader A.N., Starks D., Rose P.G., Tuller E., Gibbons H., Abushahin F., et al. Percentage UPSC, lymphovascular invasion, and tumor size are not independent predictors of recurrence. Gynecol. Oncol. 112 2, Suppl 1 (2009 Feb) S72
73. Geisler J.P., Geisler H.E., Melton M.E., and Wiemann M.C. What staging surgery should be performed on patients with uterine papillary serous carcinoma?. Gynecol. Oncol. 74 3 (1999) 465-467
74. Gehrig P.A., Van Le L., and Fowler Jr. W.C. The role of omentectomy during the surgical staging of uterine serous carcinoma. Int. J. Gynecol. Cancer. 13 2 (2003) 212-215
75. Winter III W.E., Maxwell G.L., Tian C., Carlson J.W., Ozols R.F., Rose P.G., et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 25 24 (2007 Aug 20) 3621-3627
76. Bristow R.E., Tomacruz R.S., Armstrong D.K., Trimble E.L., and Montz F.J. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J. Clin. Oncol. 20 5 (2002 Mar 1) 1248-1259
77. Bristow R.E., Duska L.R., and Montz F.J. The role of cytoreductive surgery in the management of stage IV uterine papillary serous carcinoma. Gynecol. Oncol. 81 1 (2001) 92-99
78. Bristow R.E., Zerbe M.J., Rosenshein N.B., Grumbine F.C., and Montz F.J. Stage IVB endometrial carcinoma: the role of cytoreductive surgery and determinants of survival. Gynecol. Oncol. 78 2 (2000 Aug) 85-91
79. Chi D.S., Welshinger M., Venkatraman E.S., and Barakat R.R. The role of surgical cytoreduction in Stage IV endometrial carcinoma. Gynecol. Oncol. 67 1 (1997 Oct) 56-60
80. Lambrou N.C., Gomez-Marin O., Mirhashemi R., Beach H., Salom E., Almeida-Parra Z., et al. Optimal surgical cytoreduction in patients with Stage III and Stage IV endometrial carcinoma: a study of morbidity and survival. Gynecol. Oncol. 93 3 (2004 Jun) 653-658
81. Memarzadeh S., Holschneider C.H., Bristow R.E., Jones N.L., Fu Y.S., Karlan B.Y., et al. FIGO stage III and IV uterine papillary serous carcinoma: impact of residual disease on survival. Int. J. Gynecol. Cancer 12 5 (2002) 454-458
82. Moller K.A., Gehrig P.A., Van Le L., Secord A.A., and Schorge J. The role of optimal debulking in advanced stage serous carcinoma of the uterus. Gynecol. Oncol. 94 1 (2004) 170-174
83. Thomas M.B., Mariani A., Cliby W.A., Keeney G.L., Podratz K.C., and Dowdy S.C. Role of cytoreduction in stage III and IV uterine papillary serous carcinoma. Gynecol. Oncol. 107 2 (2007) 190-193
84. Creasman W.T., Morrow C.P., Bundy B.N., Homesley H.D., Graham J.E., and Heller P.B. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group study. Cancer 60 8 Suppl (1987 Oct 15) 2035-2041
85. Morrow C.P., Bundy B.N., Kurman R.J., Creasman W.T., Heller P., Homesley H.D., et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol. Oncol.. 40 1 (1991 Jan) 55-65
86. Sood B.M., Jones J., Gupta S., Khabele D., Guha C., Runowicz C., et al. Patterns of failure after the multimodality treatment of uterine papillary serous carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 57 1 (2003) 208-216
87. Fader A.N., Drake R.D., O'Malley D.M., Gibbons H.E., Huh W.K., Havrilesky L.J., et al. Platinum/taxane-based chemotherapy with or without radiotherapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma. Cancer 115 6 (2009 May)
88. Kwon J., Ackerman I., and Franssen E. The role of abdominal-pelvic radiotherapy in the management of uterine papillary serous carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 59 5 (2004 Aug 1) 1439-1445
89. Lim P., Al Kushi A., Gilks B., Wong F., and Aquino-Parsons C. Early stage uterine papillary serous carcinoma of the endometrium: effect of adjuvant whole abdominal radiotherapy and pathologic parameters on outcome. Cancer 91 4 (2001 Feb 15) 752-757
90. Martinez A.A., Weiner S., Podratz K., Armin A.R., Stromberg J.S., Stanhope R., et al. Improved outcome at 10 years for serous-papillary/clear cell or high-risk endometrial cancer patients treated by adjuvant high-dose whole abdomino-pelvic irradiation. Gynecol. Oncol.. 90 3 (2003 Sep) 537-546
91. Mehta N., Yamada S.D., Rotmensch J., and Mundt A.J. Outcome and pattern of failure in pathologic stage I-II papillary serous carcinoma of the endometrium: implications for adjuvant radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 57 4 (2003 Nov 15) 1004-1009
92. Sutton G., Axelrod J.H., Bundy B.N., Roy T., Homesley H., Lee R.B., et al. Adjuvant whole abdominal irradiation in clinical stages I and II papillary serous or clear cell carcinoma of the endometrium: a phase II study of the Gynecologic Oncology Group. Gynecol. Oncol.. 100 2 (2006 Feb) 349-354
93. Huh W.K., Powell M., Leath III C.A., Straughn Jr. J.M., Cohn D.E., Gold M.A., et al. Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy. Gynecol. Oncol.. 91 3 (2003 Dec) 470-475
94. Fakiris A.J., Moore D.H., Reddy S.R., Look K.Y., Yiannoutsos C.T., Randall M.E., et al. Intraperitoneal radioactive phosphorus (32P) and vaginal brachytherapy as adjuvant treatment for uterine papillary serous carcinoma and clear cell carcinoma: a phase II Hoosier Oncology Group (HOG 97-01) study. Gynecol. Oncol. 96 3 (2005 Mar) 818-823
95. Dietrich III C.S., Modesitt S.C., DePriest P.D., Ueland F.R., Wilder J., Reedy M.B., et al. The efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC). Gynecol. Oncol.. 99 3 (2005) 557-563
96. Havrilesky L.J., Secord A.A., Bae-Jump V., Ayeni T., Calingaert B., Clarke-Pearson D.L., et al. Outcomes in surgical stage I uterine papillary serous carcinoma. Gynecol. Oncol.. 105 3 (2007) 677-682
97. Thomas M.B., Mariani A., Cliby W.A., Keeney G.A., Podratz K.C., and Dowdy S.C. Role of systematic lymphadenectomy and adjuvant therapy in stage I uterine papillary serous carcinoma. Gynecol. Oncol.. 107 2 (2007) 186-189
98. Kelly M.G., O'Malley D.M., Hui P., McAlpine J., Yu H., Rutherford T.J., et al. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. Gynecol. Oncol.. 98 3 (2005 Sep) 353-359
99. Fields A.L., Einstein M.H., Novetsky A.P., Gebb J., and Goldberg G.L. Pilot phase II trial of radiation "sandwiched" between combination paclitaxel/platinum chemotherapy in patients with uterine papillary serous carcinoma (UPSC). Gynecol. Oncol.. 108 1 (2008) 201-206
100. DuBeshter B., Estler K., Altobelli K., McDonald S., Glantz C., and Angel C. High-dose rate brachytherapy for Stage I/II papillary serous or clear cell endometrial cancer. Gynecol. Oncol. 94 2 (2004 Aug) 383-386
101. Elit L., Kwon J., Bentley J., Trim K., Ackerman I., and Carey M. Optimal management for surgically Stage 1 serous cancer of the uterus. Gynecol. Oncol. 92 1 (2004) 240-246
102. Grice J., Ek M., Greer B., Koh W.J., Muntz H.G., Cain J., et al. Uterine papillary serous carcinoma: evaluation of long-term survival in surgically staged patients. Gynecol. Oncol. 69 1 (1998 Apr) 69-73
103. Hamilton C.A., Liou W.S., Osann K., Berman M.L., Husain A., Teng N.N., et al. Impact of adjuvant therapy on survival of patients with early-stage uterine papillary serous carcinoma. Int. J. Radiat. Oncol., Biol., Phys. 63 3 (2005) 839-844
104. Kwon J.S., Abrams J., Sugimoto A., and Carey M.S. Is adjuvant therapy necessary for stage IA and IB uterine papillary serous carcinoma and clear cell carcinoma after surgical staging?. Int. J. Gynecol. Cancer 18 4 (2008) 820-824
105. Fader A.N., Nagel C., Axtell A.E., Zanotti K.M., Kelley J.P., Moore K.N., et al. Stage II uterine papillary serous carcinoma: carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes. Gynecol. Oncol. (2008 Dec) 30
106. Reisinger S.A., Staros E.B., Feld R., Mohiuddin M., and Lewis G.C. Preoperative radiation therapy in clinical stage II endometrial carcinoma. Gynecol. Oncol. 45 2 (1992 May) 174-178
107. Smith R.S., Kapp D.S., Chen Q., and Teng N.N. Treatment of high-risk uterine cancer with whole abdominopelvic radiation therapy. Int. J. Radiat. Oncol. Biol. Phys 48 3 (2000 Oct 1) 767-778
108. Sutton G., Axelrod J.H., Bundy B.N., Roy T., Homesley H.D., Malfetano J.H., et al. Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a gynecologic oncology group study. Gynecol. Oncol. 97 3 (2005) 755-763
109. Levenback C., Burke T.W., Silva E., Morris M., Gershenson D.M., Kavanagh J.J., et al. Uterine papillary serous carcinoma (UPSC) treated with cisplatin, doxorubicin, and cyclophosphamide (PAC). Gynecol. Oncol. 46 3 (1992 Sep) 317-321
110. Price F.V., Chambers S.K., Carcangiu M.L., Kohorn E.I., Schwartz P.E., and Chambers J.T. Intravenous cisplatin, doxorubicin, and cyclophosphamide in the treatment of uterine papillary serous carcinoma (UPSC). Gynecol. Oncol. 51 3 (1993 Dec) 383-389
111. Fleming G.F., Brunetto V.L., Cella D., Look K.Y., Reid G.C., Munkarah A.R., et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol. 22 11 (2004 Jun 1) 2159-2166
112. Fleming G.F., Filiaci V.L., Bentley R.C., Herzog T., Sorosky J., Vaccarello L., et al. Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. Ann Oncol. 15 8 (2004 Aug) 1173-1178
113. Gallion H.H., Brunetto V.L., Cibull M., Lentz S.S., Reid G., Soper J.T., et al. Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol. 21 20 (2003 Oct 15) 3808-3813
114. Thigpen J.T., Brady M.F., Homesley H.D., Malfetano J., DuBeshter B., Burger R.A., et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J. Clin. Oncol. 22 19 (2004 Oct 1) 3902-3908
115. Homesley H.D., Filiaci V., Gibbons S.K., Long H.J., Cella D., Spirtos N.M., et al. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology Group study. Gynecol. Oncol. (2008 Dec) 22
116. McMeekin D.S., Filiaci V.L., Thigpen J.T., Gallion H.H., Fleming G.F., and Rodgers W.H. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study. Gynecol. Oncol. 106 1 (2007 Jul) 16-22
117. Zanotti K.M., Belinson J.L., Kennedy A.W., Webster K.D., and Markman M. The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma. Gynecol. Oncol. 74 2 (1999 Aug) 272-277
118. Ramondetta L., Burke T.W., Levenback C., Bevers M., Bodurka-Bevers D., and Gershenson D.M. Treatment of uterine papillary serous carcinoma with paclitaxel. Gynecol. Oncol.. 82 1 (2001 Jul) 156-161
119. Hoskins P.J., Swenerton K.D., Pike J.A., Wong F., Lim P., Acquino-Parsons C., et al. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. J. Clin. Oncol. 19 20 (2001 Oct 15) 4048-4053
120. Sovak M.A., Hensley M.L., Dupont J., Ishill N., Alektiar K.M., Abu-Rustum N., et al. Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: a retrospective study. Gynecol. Oncol. 103 2 (2006) 451-457
121. Vaidya A.P., Littell R., Krasner C., and Duska L.R. Treatment of uterine papillary serous carcinoma with platinum-based chemotherapy and paclitaxel. Int. J. Gynecol. Cancer 16 Suppl 1 (2006) 267-272
122. Pectasides D., Xiros N., Papaxoinis G., Pectasides E., Sykiotis C., Koumarianou A., et al. Carboplatin and paclitaxel in advanced or metastatic endometrial cancer. Gynecol. Oncol. 109 2 (2008) 250-254
123. Chambers J.T., Chambers S.K., Kohorn E.I., Carcangiu M.L., and Schwartz P.E. Uterine papillary serous carcinoma treated with intraperitoneal cisplatin and intravenous doxorubicin and cyclophosphamide. Gynecol. Oncol. 60 3 (1996 Mar) 438-442
124. Gehrig P.A., Morris D.E., and Van Le L. Uterine serous carcinoma: a comparison of therapy for advanced-stage disease. Int. J. Gynecol. Cancer 14 3 (2004 May-Jun) 515-520
125. Hamilton C.A., Cheung M.K., Osann K., Balzer B., Berman M.L., Husain A., et al. The effect of adjuvant chemotherapy versus whole abdominopelvic radiation on the survival of patients with advanced stage uterine papillary serous carcinoma. Gynecol. Oncol. 103 2 (2006) 679-683
126. Steed H., Manchul L., Rosen B., Fyles A., Lockwood G., Laframboise S., et al. Uterine papillary serous carcinoma: evaluation of multimodality treatment with abdominopelvic radiotherapy and chemotherapy. Int. J. Gynecol. Cancer 16 Suppl 1 (2006 Jan-Feb) 278-285
127. Gitsch G., Friedlander M.L., Wain G.V., and Hacker N.F. Uterine papillary serous carcinoma. A clinical study. Cancer 75 9 (1995 May 1) 2239-2243
128. Goldberg H., Miller R.C., Abdah-Bortnyak R., Steiner M., Yildiz F., Meirovitz A., et al. Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN). Gynecol. Oncol. 108 2 (2008) 298-305
129. Randall M.E., Filiaci V.L., Muss H., Spirtos N.M., Mannel R.S., Fowler J., et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol. 24 1 (2006 Jan 1) 36-44
130. Low J.S., Wong E.H., Tan H.S., Yap S.P., Chua E.J., Sethi V.K., et al. Adjuvant sequential chemotherapy and radiotherapy in uterine papillary serous carcinoma. Gynecol. Oncol. 97 1 (2005) 171-177
131. Duska L.R., Berkowitz R., Matulonis U., Muto M., Goodman A., McIntyre J.F., et al. A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer. Gynecol. Oncol. 96 1 (2005) 198-203
132. Alvarez Secord A., Havrilesky L.J., Bae-Jump V., Chin J., Calingaert B., Bland A., et al. The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer. Gynecol. Oncol.. 107 2 (2007 Nov) 285-291
133. Secord A.A., Havrilesky L.J., O Malley D.M., Bae-Jump V., Fleming N.D., Broadwater G., et al. A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer. Gynecol. Oncol.. 112 2, Suppl. 1 (2009 Feb) S12
134. Abramovich D., Markman M., Kennedy A., Webster K., and Belinson J. Serum CA-125 as a marker of disease activity in uterine papillary serous carcinoma. J. Cancer Res. Clin. Oncol. 125 12 (1999 Dec) 697-698
135. Price F.V., Chambers S.K., Carcangiu M.L., Kohorn E.I., Schwartz P.E., and Chambers J.T. CA 125 may not reflect disease status in patients with uterine serous carcinoma. Cancer 82 9 (1998 May 1) 1720-1725
136. Niloff J.M., Klug T.L., Schaetzl E., Zurawski Jr. V.R., Knapp R.C., and Bast Jr. R.C. Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix. Am. J. Obstet. Gynecol. 148 8 (1984 Apr 15) 1057-1058
137. Duk J.M., Aalders J.G., Fleuren G.J., and de Bruijn H.W. CA 125: a useful marker in endometrial carcinoma. Am. J. Obstet. Gynecol.. 155 5 (1986 Nov) 1097-1102
138. Patsner B., Mann W.J., Cohen H., and Loesch M. Predictive value of preoperative serum CA 125 levels in clinically localized and advanced endometrial carcinoma. Am. J. Obstet. Gynecol.. 158 2 (1988 Feb) 399-402
139. Sood A.K., Buller R.E., Burger R.A., Dawson J.D., Sorosky J.I., and Berman M. Value of preoperative CA 125 level in the management of uterine cancer and prediction of clinical outcome. Obstet. Gynecol.. 90 3 (1997 Sep) 441-447
140. Olawaiye A.B., Rauh-Hain J.A., Withiam-Leitch M., Rueda B., Goodman A., and del Carmen M.G. Utility of pre-operative serum CA-125 in the management of uterine papillary serous carcinoma. Gynecol. Oncol.. 110 3 (2008) 293-298
141. Moore R.G., Brown A.K., Miller M.C., Badgwell D., Lu Z., Allard W.J., et al. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol. Oncol.. 110 2 (2008 Aug) 196-201
142. Yurkovetsky Z., Ta'asan S., Skates S., Rand A., Lomakin A., Linkov F., et al. Development of multimarker panel for early detection of endometrial cancer. High diagnostic power of prolactin. Gynecol. Oncol.. 107 1 (2007 Oct) 58-65
143. Diefenbach C.S., Shah Z., Iasonos A., Barakat R.R., Levine D.A., Aghajanian C., et al. Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer. Gynecol. Oncol.. 104 2 (2007 Feb) 435-442
144. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353 16 (2005 Oct 20) 1659-1672
145. Robert N., Leyland-Jones B., Asmar L., Belt R., Ilegbodu D., Loesch D., et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J. Clin. Oncol. 24 18 (2006 Jun 20) 2786-2792
146. Goff B.A. Uterine papillary serous carcinoma: what have we learned over the past quarter century?. Gynecol. Oncol. 98 3 (2005) 341-343
147. Podratz K.C., and Mariani A. Uterine papillary serous carcinomas: the exigency for clinical trials. Gynecol. Oncol. 91 3 (2003) 461-462